Helicore
5 known investors
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Investors · 5
Longitude CapitalMenlo Park · $10M – $30M
OrbiMedNew York · $1M – $75M
Versant VenturesreportedSan Francisco · $250K – $5M
Wellington ManagementreportedBoston · $5M – $50M
Also in the syndicate · 1
Versantlead
Funding
SEC filings, press & company announcements- Undisclosed amountseries AJan 2025
OrbiMed (lead), Versant (lead), Longitude Capital, Wellington Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Helicore do?
- Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
- Who are Helicore's investors?
- Helicore's investors include Longitude Capital, OrbiMed, Versant Ventures, Wellington Management.